Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class exposed, relapsed and refractory multiple myeloma (RRMM) in the phase 2 KarMMa (Efficacy and Safety Study of bb2121 in Subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Delforge, Michel, Shah, Nina, Miguel, Jesús San F., Braverman, Julia, Dhanda, Devender S., Shi, Ling, Guo, Shien, Yu, Peiwen, Liao, Weiqin, Campbell, Timothy B., Munshi, Nikhil C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864645/
https://www.ncbi.nlm.nih.gov/pubmed/34933328
http://dx.doi.org/10.1182/bloodadvances.2021005913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864645/
https://www.ncbi.nlm.nih.gov/pubmed/34933328
http://dx.doi.org/10.1182/bloodadvances.2021005913

Ejemplares similares